Why Sun Pharma may move part of its $12bn Organon funding into rupee debt

Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) is preparing a potentially significant shift in the financing structure surrounding its proposed acquisition of Organon & Co., with the board scheduled to meet on October 12 to consider issuing up to ₹15,000 crore of listed, rated, unsecured and redeemable non-convertible debentures. The company’s October 7 regulatory filing says the securities could be placed privately in one or more tranches, making ₹15,000 crore an enabling ceiling rather than debt that has already been issued.

The filing itself does not specify the use of proceeds, so the NCD proposal should not be described as formally earmarked for Organon. The financing context, however, is difficult to ignore. Sun Pharma is simultaneously seeking shareholder approval to increase its borrowing limit from ₹50,000 crore to ₹70,000 crore and permit security arrangements connected with financing facilities of up to $12 billion for the Organon transaction.

That places the latest ₹15,000 crore proposal inside a much larger balance-sheet transformation. Sun entered the Organon transaction from a net-cash position; if the acquisition closes as planned, the company expects to absorb a business with substantial existing debt and move to a materially leveraged combined capital structure.

Why is Sun Pharma considering as much as ₹15,000 crore of NCDs now?

The timing closely follows reporting that Sun Pharma has been evaluating domestic rupee bonds as a way to replace part of short-term acquisition financing with longer-duration funding. Reuters reporters Khushi Malhotra and Dharamraj Dhutia reported on September 29, citing three sources familiar with the plans, that Sun Pharma was preparing to raise around ₹10,000 crore through rupee-denominated bonds to partly refinance an approximately $12 billion, 18-month bridge loan arranged for the Organon acquisition. Reuters said Sun Pharma had not commented on that report.

The formal board notice now provides primary-source confirmation that Sun is considering a domestic NCD programme, although the approved ceiling is larger than the approximately ₹10,000 crore figure previously reported by Reuters. The board will consider up to ₹15,000 crore, giving management room to decide the actual amount and timing depending on funding requirements and debt-market conditions.

At the October 7 exchange rate used by Reuters, ₹15,000 crore is approximately $1.55 billion. Even if Sun were eventually to issue the full amount, that would replace only around 13% of a near-$12 billion bridge facility, indicating that domestic NCDs would likely represent one component of a broader refinancing structure rather than the complete takeout of acquisition financing.

That distinction matters because a bridge loan is designed to provide temporary certainty around an acquisition closing. Once the transaction is completed, companies commonly replace bridge financing progressively with bonds, term loans, internal cash flow or other longer-dated funding.

How large is the Organon transaction relative to Sun Pharma’s existing balance sheet?

Sun Pharma agreed in April to acquire 100% of Organon for $14 per share in cash, implying approximately $3.99 billion of equity value and an enterprise value of about $11.75 billion. The company originally said it expected to use $2 billion to $2.5 billion of cash on hand and fund the remaining $9.25 billion to $9.75 billion through committed bank financing.

That is a transformational transaction even for India’s largest listed pharmaceutical company. Sun’s April investor presentation showed FY25 revenue of approximately $6.2 billion, while Organon generated a similar $6.2 billion, implying a combined business of roughly $12.4 billion before considering subsequent growth. The same presentation showed combined EBITDA of about $3.7 billion and free cash flow before financing of approximately $2.5 billion based on the reference periods used in the transaction analysis.

The acquisition therefore roughly doubles Sun’s revenue scale while introducing significant leverage. Sun characterised itself as net cash positive before the deal, while Organon carried net debt equivalent to about four times EBITDA. The company’s acquisition model placed the combined entity at approximately 2.3 times net debt to EBITDA following successful consolidation.

That projected leverage is manageable compared with many large global pharmaceutical acquisitions, but it is materially different from Sun’s historical balance-sheet position. Refinancing cost, tenor and debt-repayment speed will consequently become more important drivers of shareholder returns after closing.

Why could rupee debt be attractive compared with leaving the bridge loan in place?

Bridge facilities provide speed but are not usually intended to remain the permanent financing structure for a multiyear acquisition. An 18-month facility creates a relatively short maturity window, forcing the borrower to refinance, repay or replace the debt on a defined timetable.

Reuters’ September reporting said Sun was exploring two-, three- and four-year domestic bonds at a time when elevated U.S. Treasury yields had made dollar funding relatively expensive. The publication also reported a broader increase in Indian companies examining domestic debt markets as dollar borrowing costs rose.

Rupee NCDs could diversify Sun’s lender base and stretch portions of the acquisition debt over longer maturities. The company would also reduce dependence on one large short-term bridge facility, although exact savings cannot be calculated until coupon rates, maturities and tranche sizes are disclosed.

The unsecured structure is another notable element. Sun’s board will consider listed, rated and unsecured NCDs, which means investors would rely on the company’s overall creditworthiness rather than a specific asset package supporting each debenture.

The ultimate economics will therefore depend on the coupon demanded by institutional investors. Domestic financing only creates value if the all-in cost, maturity profile and currency exposure compare favourably with alternative bank or overseas funding.

Why has Sun Pharma sought a ₹70,000 crore borrowing limit before the Organon deal closes?

Sun’s October postal-ballot process seeks shareholder approval to increase the company’s statutory borrowing ceiling from ₹50,000 crore to ₹70,000 crore. It is also seeking to expand limits for investments, loans, guarantees and securities to ₹80,000 crore and obtain authority to create encumbrances connected with financing facilities aggregating as much as $12 billion for the acquisition.

These are enabling approvals rather than evidence that Sun immediately plans to carry ₹70,000 crore of standalone debt. They give the company sufficient corporate authority to arrange acquisition financing, refinance it and provide guarantees or security where required.

Shareholder voting runs from October 2 through October 31, with results due on or before November 3. That means the October 12 board meeting on the ₹15,000 crore NCD programme will occur before the postal-ballot process itself has concluded.

The sequencing suggests Sun is building financing flexibility ahead of the acquisition close rather than waiting until the last moment to restructure the bridge. The company continues to expect the Organon acquisition to close in early 2027, subject to remaining customary conditions. Sun confirmed after its June quarter that Organon shareholders had already approved the transaction.

Can Sun Pharma’s current earnings support the larger post-Organon debt burden?

Sun entered the financing phase with strong operating cash-generation capacity. Q1 FY27 sales increased 10.1% year on year to ₹15,183.6 crore, while EBITDA rose 2.7% to ₹4,417.7 crore for a 28.9% margin. Adjusted net profit was ₹3,089.4 crore, up 3.1%, and global Innovative Medicines sales reached $351 million, representing 21.9% of consolidated sales.

India remained particularly strong, with formulation sales rising 16% to ₹5,474.9 crore. U.S. formulation revenue was weaker at $427 million, down 9.7%, although the growing Innovative Medicines portfolio partly offset pressure in the generic business.

Organon would materially increase the cash-flow base available for debt servicing. Sun’s original transaction presentation estimated combined annual free cash flow before financing of around $2.5 billion and said strong cash generation would support debt repayment. Those estimates are based on FY25 Sun and calendar-2025 Organon reference figures, so they should be treated as transaction assumptions rather than current reported combined results.

The central financing thesis is therefore straightforward: Sun is accepting higher leverage to acquire a business that itself generates substantial cash. Whether that creates value depends on integration, refinancing costs, Organon’s underlying earnings resilience and how quickly the combined cash flows reduce debt.

What does the ₹15,000 crore NCD plan mean for Sun Pharma shareholders?

The proposal does not create equity dilution because NCDs are debt securities rather than convertible shares. The trade-off appears instead through leverage and interest expense.

At the October 7 NSE close of ₹1,781, Sun Pharma had a market capitalisation of approximately ₹4.27 lakh crore. A full ₹15,000 crore NCD programme would therefore equal only around 3.5% of equity market value, but market capitalisation is not the correct measure of repayment capacity. The more relevant metrics after the Organon acquisition will be net debt, EBITDA, free cash flow and interest coverage.

Sun shares entered October 8 about 13% below their July 31 52-week high, closing October 7 at ₹1,781 on the NSE. The latest NCD announcement was made after that trading session, so the October 8 market will provide the first opportunity for investors to respond to the formal ₹15,000 crore ceiling.

The October 12 board decision should provide the next hard milestone. If the proposal is approved, the market will then need tranche sizes, maturities, coupon rates and use-of-proceeds clarity before the real refinancing economics can be assessed.

Sun Pharma’s balance sheet is about to look very different from the one investors have known for years. The proposed NCD programme is important not because ₹15,000 crore alone changes the company, but because it marks the beginning of the longer-term debt architecture required to absorb an $11.75 billion acquisition and turn Organon’s cash flows into a successful deleveraging story.